Interleukin-23 · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Interleukin-23 shows approved-linked disease relevance led by psoriasis. 5 more disease programs remain visible in the same review block. 7 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P29460. Start with psoriasis, then reuse UniProt P29460 as the stable protein anchor across project notes and exports.
Start with psoriasis, then reuse UniProt P29460 as the stable protein anchor across project notes and exports.
Interleukin-23 shows approved-linked disease relevance led by psoriasis. 5 more disease programs remain visible in the same review block. 7 linked drugs remain visible in the same block.
Start review with psoriasis because it currently carries approved-linked support. Linked drugs include BRIAKINUMAB, EBDAROKIMAB, GUSELKUMAB, MIRIKIZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyInterleukin-12 subunit beta
Review this target as Interleukin-23, mapped to UniProt P29460. ChEMBL maps the protein component as Interleukin-12 subunit beta. Sequence length is 328 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Interleukin-23 as ChEMBL target CHEMBL2364154, mapped to UniProt P29460. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Interleukin-23 is the right protein anchor across sources, using UniProt P29460 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why psoriasis is currently framed as approved-linked support. It currently carries 7 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Interleukin-23 |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P29460 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Interleukin-12 subunit beta |
| UniProt Accession | P29460 |
| Component Type | Protein |
| Sequence Length | 328 aa |
Interleukin-12 subunit beta
Review this target as Interleukin-23, mapped to UniProt P29460. ChEMBL maps the protein component as Interleukin-12 subunit beta. Sequence length is 328 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Interleukin-23 shows approved-linked disease relevance led by psoriasis. 5 more disease programs remain visible in the same review block.
Start review with psoriasis because it currently carries approved-linked support. Linked drugs include BRIAKINUMAB, EBDAROKIMAB, GUSELKUMAB, MIRIKIZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.